Members of the Cancer Prevention and Control Program (PC) conduct population sciences and chemoprevention research that has significant potential to reduce the cancer burden in Colorado, the Rocky Mountain Region and beyond. PC has three main focus groups: 1) behavioral research in primary and secondary prevention, 2) chemoprevention research, and 3) cancer outcomes and cancer survivorship research. During the current CCSG program members have made numerous contributions to the science of cancer prevention and control, including: 1) several large research clinical trials (RCTs) that have demonstrated the efficacy of tailored print materials to promote fruit and vegetable consumption, colorectal cancer screening and smoking cessation;2) a large school-based program and a monumental effort that targeted the outdoor winter recreation industry that successfully promoted sun protection;3) a robust program of laboratory research that has demonstrated the chemoprevention properties of silibinin in animal models for prostate, lung, colorectal, and bladder cancer, as well as grape seed extract for prostate and colon cancer;4) a large multi-site RCT demonstrating the efficacy of telephone counseling on psychosocial outcomes among breast cancer survivors;5) a large multi-site RCT that demonstrated the efficacy of a cognitive remediation program for young survivors of childhood cancer;6) two of the most definitive programs of research in cancer epidemiology that have examined and identified risk factors for breast cancer among Latinas, and nevus development among young children in Colorado, and 7) numerous exemplars of translational science and dissemination research in the areas of sun protection, diet, nutrition and physical activity, tobacco control, colorectal cancer screening and chemoprevention research. PC includes 31 Full Members and 32 Associate Members drawn from 17 academic departments and schools within the University of Colorado Denver, University of Colorado Boulder, the Veterans Administration (Denver), Colorado State University, Denver Health Medical Center, The Children's Hospital (Denver) and Kaiser Permanente of Colorado. During the current CCSG, program members have published 594 peer-reviewed cancer-related papers, compared to 306 during the previous CCSG. 37% of these publications were collaborative, with 23% being interprogrammatic or both interprogrammatic and intraprogrammatic. Peer reviewed, cancer-related funding has also increased from $8.9M (2005) to $13.3M in 2010. This represents a per capita increase of 140% from $269K to over $640K per member.

Public Health Relevance

To further reduce the cancer burden in the U.S., a robust program of research and translational science in cancer prevention and control is needed, which this program provides to UCCC, the State of Colorado and beyond.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-25
Application #
8567541
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
25
Fiscal Year
2013
Total Cost
$86,776
Indirect Cost
$28,414
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Coleman, Carrie B; Lang, Julie; Sweet, Lydia A et al. (2018) Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice. J Virol 92:
Petersen, Dennis R; Orlicky, David J; Roede, James R et al. (2018) Aberrant expression of redox regulatory proteins in patients with concomitant primary Sclerosing cholangitis/inflammatory bowel disease. Exp Mol Pathol 105:32-36
Couts, Kasey L; Bemis, Judson; Turner, Jacqueline A et al. (2018) ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther 17:222-231
Nicholson, Andrew G; Torkko, Kathleen; Viola, Patrizia et al. (2018) Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. J Thorac Oncol 13:205-217
Greaves, Sarah A; Peterson, Jacob N; Torres, Raul M et al. (2018) Activation of the MEK-ERK Pathway Is Necessary but Not Sufficient for Breaking Central B Cell Tolerance. Front Immunol 9:707
Thompson, Scott B; Wigton, Eric J; Krovi, Sai Harsha et al. (2018) The Formin mDia1 Regulates Acute Lymphoblastic Leukemia Engraftment, Migration, and Progression in vivo. Front Oncol 8:389
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Sang, Allison; Danhorn, Thomas; Peterson, Jacob N et al. (2018) Innate and adaptive signals enhance differentiation and expansion of dual-antibody autoreactive B cells in lupus. Nat Commun 9:3973
Ye, Haobin; Adane, Biniam; Khan, Nabilah et al. (2018) Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. Cancer Cell 34:659-673.e6
Flannery, Patrick C; DeSisto, John A; Amani, Vladimir et al. (2018) Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncol Rep 39:455-464

Showing the most recent 10 out of 1634 publications